Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
11 2020
Historique:
received: 28 04 2020
accepted: 19 10 2020
entrez: 12 11 2020
pubmed: 13 11 2020
medline: 26 1 2021
Statut: epublish

Résumé

Effective health system interventions may help address the disproportionate burden of diabetes in low- and middle-income countries (LMICs). We assessed the impact of health system interventions to improve outcomes for adults with type 2 diabetes in LMICs. We searched Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus from inception of each database through February 24, 2020. We included randomized controlled trials (RCTs) of health system interventions targeting adults with type 2 diabetes in LMICs. Eligible studies reported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-effectiveness. We conducted a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c). GRADE and Cochrane Effective Practice and Organisation of Care methods were used to assess risk of bias for the glycemic outcome and to prepare a summary of findings table. Of the 12,921 references identified in searches, we included 39 studies in the narrative review of which 19 were cluster RCTs and 20 were individual RCTs. The greatest number of studies were conducted in the East Asia and Pacific region (n = 20) followed by South Asia (n = 7). There were 21,080 total participants enrolled across included studies and 10,060 total participants in the meta-analysis of HbA1c when accounting for the design effect of cluster RCTs. Non-glycemic outcomes of mortality, health-related quality of life, and cost-effectiveness had sparse data availability that precluded quantitative pooling. In the meta-analysis of HbA1c from 35 of the included studies, the mean difference was -0.46% (95% CI -0.60% to -0.31%, I2 87.8%, p < 0.001) overall, -0.37% (95% CI -0.64% to -0.10%, I2 60.0%, n = 7, p = 0.020) in multicomponent clinic-based interventions, -0.87% (-1.20% to -0.53%, I2 91.0%, n = 13, p < 0.001) in pharmacist task-sharing studies, and -0.27% (-0.50% to -0.04%, I2 64.1%, n = 7, p = 0.010) in trials of diabetes education or support alone. Other types of interventions had few included studies. Eight studies were at low risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 16 studies were at high risk. The certainty of evidence for glycemic control by subgroup was moderate for multicomponent clinic-based interventions but was low or very low for other intervention types. Limitations include the lack of consensus definitions for health system interventions, differences in the quality of underlying studies, and sparse data availability for non-glycemic outcomes. In this meta-analysis, we found that health system interventions for type 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available from rural areas or low- or lower-middle-income countries. Multicomponent clinic-based interventions had the strongest evidence for glycemic benefit among intervention types. Further research is needed to assess non-glycemic outcomes and to study implementation in rural and low-income settings.

Sections du résumé

BACKGROUND
Effective health system interventions may help address the disproportionate burden of diabetes in low- and middle-income countries (LMICs). We assessed the impact of health system interventions to improve outcomes for adults with type 2 diabetes in LMICs.
METHODS AND FINDINGS
We searched Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus from inception of each database through February 24, 2020. We included randomized controlled trials (RCTs) of health system interventions targeting adults with type 2 diabetes in LMICs. Eligible studies reported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-effectiveness. We conducted a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c). GRADE and Cochrane Effective Practice and Organisation of Care methods were used to assess risk of bias for the glycemic outcome and to prepare a summary of findings table. Of the 12,921 references identified in searches, we included 39 studies in the narrative review of which 19 were cluster RCTs and 20 were individual RCTs. The greatest number of studies were conducted in the East Asia and Pacific region (n = 20) followed by South Asia (n = 7). There were 21,080 total participants enrolled across included studies and 10,060 total participants in the meta-analysis of HbA1c when accounting for the design effect of cluster RCTs. Non-glycemic outcomes of mortality, health-related quality of life, and cost-effectiveness had sparse data availability that precluded quantitative pooling. In the meta-analysis of HbA1c from 35 of the included studies, the mean difference was -0.46% (95% CI -0.60% to -0.31%, I2 87.8%, p < 0.001) overall, -0.37% (95% CI -0.64% to -0.10%, I2 60.0%, n = 7, p = 0.020) in multicomponent clinic-based interventions, -0.87% (-1.20% to -0.53%, I2 91.0%, n = 13, p < 0.001) in pharmacist task-sharing studies, and -0.27% (-0.50% to -0.04%, I2 64.1%, n = 7, p = 0.010) in trials of diabetes education or support alone. Other types of interventions had few included studies. Eight studies were at low risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 16 studies were at high risk. The certainty of evidence for glycemic control by subgroup was moderate for multicomponent clinic-based interventions but was low or very low for other intervention types. Limitations include the lack of consensus definitions for health system interventions, differences in the quality of underlying studies, and sparse data availability for non-glycemic outcomes.
CONCLUSIONS
In this meta-analysis, we found that health system interventions for type 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available from rural areas or low- or lower-middle-income countries. Multicomponent clinic-based interventions had the strongest evidence for glycemic benefit among intervention types. Further research is needed to assess non-glycemic outcomes and to study implementation in rural and low-income settings.

Identifiants

pubmed: 33180775
doi: 10.1371/journal.pmed.1003434
pii: PMEDICINE-D-20-01702
pmc: PMC7660583
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003434

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK092926
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH110599
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Diabetes Care. 2020 Apr;43(4):767-775
pubmed: 32051243
Nurs Health Sci. 2015 Sep;17(3):362-9
pubmed: 25818472
EClinicalMedicine. 2019 Nov 19;17:100211
pubmed: 31891144
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
BMC Health Serv Res. 2019 Jun 24;19(1):409
pubmed: 31234840
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Int J Clin Pharm. 2013 Feb;35(1):79-86
pubmed: 23161124
Diabetes Technol Ther. 2016 Apr;18(4):240-51
pubmed: 26914371
BMJ Open. 2015 Sep 25;5(9):e008932
pubmed: 26408831
Diabetes Care. 2006 May;29(5):1007-11
pubmed: 16644629
J Diabetes. 2018 Dec;10(12):965-976
pubmed: 29877609
BJGP Open. 2018 Dec 12;2(4):bjgpopen18X101618
pubmed: 30723803
Patient Prefer Adherence. 2014 Sep 04;8:1185-94
pubmed: 25214772
Int J Clin Pharm. 2018 Apr;40(2):345-353
pubmed: 29435911
Prim Care Diabetes. 2017 Apr;11(2):154-161
pubmed: 28122690
Rev Saude Publica. 2010 Feb;44(1):185-9
pubmed: 20140343
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Circulation. 2018 Nov 10;:
pubmed: 30586732
Diabet Med. 2017 Mar;34(3):440-450
pubmed: 27278933
Front Public Health. 2018 Sep 19;6:252
pubmed: 30283767
J Pharm Pharm Sci. 2011;14(2):249-63
pubmed: 21733413
J Gen Intern Med. 2020 Jan;35(1):87-94
pubmed: 31512187
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Clin Transl Endocrinol. 2017 Jan 03;7:33-41
pubmed: 29067248
Prim Care Diabetes. 2010 Oct;4(3):145-53
pubmed: 20478753
Diabetes Care. 2016 May;39(5):780-7
pubmed: 26965719
Ann Fam Med. 2015 Aug;13 Suppl 1:S50-8
pubmed: 26304972
PLoS One. 2014 Aug 14;9(8):e103754
pubmed: 25121789
Telemed J E Health. 2016 Aug;22(8):666-74
pubmed: 26938489
JMIR Mhealth Uhealth. 2018 Jul 13;6(7):e137
pubmed: 30006326
Diabetes Res Clin Pract. 2012 Oct;98(1):38-45
pubmed: 22784926
BMC Public Health. 2019 Nov 21;19(1):1542
pubmed: 31752801
J Manag Care Pharm. 2012 Sep;18(7):516-26
pubmed: 22971205
J Res Med Sci. 2011 Mar;16 Suppl 1:S412-8
pubmed: 22247727
Glob Heart. 2019 Dec;14(4):355-365
pubmed: 31523014
Bull World Health Organ. 2011 Dec 1;89(12):907-12
pubmed: 22271948
Lancet Glob Health. 2019 Jun;7(6):e761-e771
pubmed: 31097278
Diabet Med. 2014 Aug;31(8):987-93
pubmed: 24766179
PLoS One. 2018 Mar 29;13(3):e0195086
pubmed: 29596495
Diabetes Care. 2013 Jul;36(7):1947-53
pubmed: 23393217
Diabetes Care. 2018 Jun;41(6):1312-1320
pubmed: 29784698
J Pharm Bioallied Sci. 2019 Jan-Mar;11(1):69-76
pubmed: 30906142
Patient Prefer Adherence. 2019 Aug 14;13:1353-1362
pubmed: 31616135
Prim Care Diabetes. 2008 Feb;2(1):31-7
pubmed: 18684418
BMJ Open. 2014 Oct 16;4(10):e005983
pubmed: 25324324
Ann Intern Med. 2016 Sep 20;165(6):399-408
pubmed: 27398874
Ann Intern Med. 2015 Dec 1;163(11):848-60
pubmed: 26414227
BMC Med Res Methodol. 2009 Dec 04;9:80
pubmed: 19961608
BMJ. 2011 Feb 10;342:d549
pubmed: 21310794
Prim Health Care Res Dev. 2017 Jan;18(1):35-49
pubmed: 27640303
Diabetes Care. 2018 May;41(5):1097-1105
pubmed: 29678866
Lancet. 2015 Aug 8;386(9993):569-624
pubmed: 25924834
BMC Med Res Methodol. 2006 May 03;6:20
pubmed: 16672056
Ann Intern Med. 2019 Nov 5;171(9):677-679
pubmed: 31357212
World J Diabetes. 2016 May 25;7(10):209-29
pubmed: 27226816
BMC Fam Pract. 2016 Nov 14;17(1):157
pubmed: 27842495
Lancet. 2012 Jun 16;379(9833):2252-61
pubmed: 22683130
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667
pubmed: 28688818
Arch Gerontol Geriatr. 2015 Jan-Feb;60(1):82-8
pubmed: 25456892
Cochrane Database Syst Rev. 2015 Aug 04;(8):CD011163
pubmed: 26272648
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):271-6
pubmed: 25301007
PLoS One. 2019 Apr 8;14(4):e0214454
pubmed: 30958868
J Diabetes Res. 2019 Jan 3;2019:6516581
pubmed: 30719455
PLoS Med. 2016 Nov 22;13(11):e1002178
pubmed: 27875542
Health Policy Plan. 2013 Jan;28(1):41-50
pubmed: 22407017
Curr Pharm Des. 2016;22(42):6469-6476
pubmed: 27526787
PLoS Med. 2019 Mar 1;16(3):e1002751
pubmed: 30822339
J Health Care Poor Underserved. 2014 Feb;25(1):72-93
pubmed: 24509014

Auteurs

David Flood (D)

Center for Research in Indigenous Health, Wuqu' Kawoq, Tecpán, Guatemala.
Division of Hospital Medicine, Department of Internal Medicine, National Clinician Scholars Program, University of Michigan, Ann Arbor, Michigan, United States of America.

Jessica Hane (J)

Medicine-Pediatrics Residency Program, University of Minnesota, Minneapolis, Minnesota, United States of America.

Matthew Dunn (M)

School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America.

Sarah Jane Brown (SJ)

Health Sciences Libraries, University of Minnesota, Minneapolis, Minnesota, United States of America.

Bradley H Wagenaar (BH)

Department of Global Health, University of Washington, Seattle, Washington, United States of America.
Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.

Elizabeth A Rogers (EA)

Division of General Internal Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America.
Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States of America.

Michele Heisler (M)

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan United States of America.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan United States of America.
Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan United States of America.

Peter Rohloff (P)

Center for Research in Indigenous Health, Wuqu' Kawoq, Tecpán, Guatemala.

Vineet Chopra (V)

Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan United States of America.
Division of Hospital Medicine, Department of Medicine, University of Michigan, Ann Arbor, Michigan United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH